Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod and Pseudoephedrine Interaction Study
NCT03644576Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) and ulcerative colitis (UC) comparing Ozanimod with Placebo (2 arms). Primary endpoint: Cardiovascular analysis (Blood Pressure and Heart Rate). Started Jul 2018; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03644576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644576.